Comparison of the Prognostic Value of PET Metabolic Parameters and Postoperative Pathologic Response After Neoadjuvant Immunochemotherapy in Non-Small Cell Lung Cancer.
Aug 2026· Clinical Nuclear Medicine· 0 citations· 25 references
Medicine
TL;DR
The combination of serial PET metabolic parameters and postoperative pathologic response in a joint model improves prognostic prediction in NSCLC following neoadjuvant immunotherapy plus chemotherapy.
Abstract
Objective
This study aimed to evaluate the prognostic value of serial PET/CT metabolic parameters and postoperative pathologic response separately, compare their predictive performance, and further assess their combined prognostic value in patients with non-small cell lung cancer (NSCLC) undergoing neoadjuvant immunotherapy plus chemotherapy.
Methods
We retrospectively analyzed 219 NSCLC patients who received neoadjuvant immunotherapy plus chemotherapy, followed by surgery. Pre- and post-treatment PET/CT metabolic parameters assessed by iPERCIST and postoperative pathologic response were collected. Their associations with disease-free survival (DFS) were evaluated using ROC and Kaplan-Meier analyses.
Results
During a median follow-up of 24.9 months, 59 patients (26.9%) experienced recurrence. PET metabolic parameters, particularly post-treatment parameters and their percentage changes (ΔPET), demonstrated significant prognostic value for DFS. According to iPERCIST, patients achieving imaging complete metabolic response (iCMR) demonstrated superior DFS compared with non-iCMR patients (median DFS not reached vs. 44.9 mo, P=0.001). Similarly, patients achieving pathologic complete response (pCR) or major pathologic response (MPR) showed improved DFS (P=0.008 and 0.002, respectively). Combined stratification demonstrated that patients with both iCMR and pCR had the most favorable outcomes compared with other groups (P=0.003).
Conclusions
Serial PET metabolic parameters and postoperative pathologic response hold significant prognostic value following neoadjuvant immunotherapy plus chemotherapy in NSCLC. The combination of serial PET metabolic parameters and postoperative pathologic response in a joint model improves prognostic prediction in NSCLC following neoadjuvant immunotherapy plus chemotherapy.
Combining CT radiomics and SUVmax with clinicopathological biomarkers yielded the highest numerical discrimination for pCR, but improvement over the Clinical model was modest.
Filiz Hatipoğlu, Ozcan Senmevsim, E. Kahraman et al.· Nuclear medicine communicati...· 0 citations
INTRODUCTION
Neoadjuvant chemotherapy using paclitaxel, carboplatin, and cetuximab (PCE-NAC) is used in patients with locally advanced head and neck squamous cell carcinoma (HNSCC); however, predictors of survival outcome remain unclear. This study aimed to evaluate the prognostic value of the pathological response to...
Kei Suzuki, Yushi Ueki, Y. Ohno et al.· Oral Oncology· 0 citations
Background: Pathological complete response (pCR) following neoadjuvant systemic therapy is an important prognostic indicator in triple-negative breast cancer (TNBC). Nevertheless, identifying clinicopathological characteristics associated with treatment response remains essential. This study aimed to evaluate factors a...
BACKGROUND
Neoadjuvant chemotherapy (NAC) followed by surgery is the standard treatment for locally advanced gastric cancer (LAGC). However, post-therapy staging based on ypTNM mainly reflects residual pathological status and does not capture pretreatment disease burden or the extent of tumor regression after NAC, limi...
Wei-Feng Chen, Hua-Long Zheng, Ling-Kang Zhang et al.· European Journal of Surgical...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.